Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will compare two different formulations of vabicaserin.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| vabicaserin | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetic parameters including plasma concentrations, Cmax, and AUC. | 2 months |
| Measure | Description | Time Frame |
|---|---|---|
| Safety assessment as measured by evaluating any reported adverse events, scheduled physical examinations, vital sign measurements, ECGs, and clinical laboratory results. | 2 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Wyeth is now a wholly owned subsidiary of Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brighton | Massachusetts | 2135 | United States |
Not provided
| ID | Term |
|---|---|
| C556517 | vabicaserin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided